Injectable and swellable microspheres for tissue bulking

ABSTRACT

The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions.

This application is a continuation application of pending U.S. patentapplication Ser. No. 12/197,187 titled INJECTABLE AND SWELLABLEMICROSPHERES FOR TISSUE BULKING, which was filed on Aug. 22, 2008, whichis a continuation application of abandoned U.S. patent application Ser.No. 09/528,989, titled INJECTABLE AND SWELLABLE MICROSPHERES FOR TISSUEBULKING, filed Mar. 20, 2000, each of which is incorporated herein byreference in its entirety.

1. FIELD OF INVENTION

The present invention relates to tissue bulking, particularly for thetreatment of gastro-esophageal reflux disease, urinary incontinence, orurinary reflux disease, using injectable compositions comprisingswellable hydrophilic microspheres.

2. BACKGROUND OF THE INVENTION

2.1 Gastro-Esophageal Reflux Disease (“GERD”)

Although Gastro-esophageal reflux is a normal physiological phenomenon,in some cases it is a pathophysiological situation that can result in avariety of symptoms which may become severe in extreme cases.Gastro-Esophageal Reflux Disease (“GERD”), describes a backflow ofacidic and enzymatic liquid from the stomach to the esophagus. It causesburning sensations behind the sternum that may be accompanied byregurgitation of gastric acid into the mouth or even the lung.Complications of GERD which define the severity of the disease includeesophageal tissue erosion, and esophageal ulcer wherein normalepithelium is replaced by a pathological tissue.

Statistical data indicate that about 35% of the American populationsuffer from heartburn at least once a month and between 5 to 10% once aday. More importantly for this kind of disease about 2% of the Americanpopulation suffer from GERD based on medical evidence data fromendoscopic examination. This disease is related to the age ofindividuals and seems to increase after 40 years of age. (Nebel O. T. etal., Am. J. Dig. Dis., 21(11):953-956 (1976)).

Normally, after a meal the lower esophageal sphincter remains closed,but in patients with GERD, it relaxes and allows some acidic material toreflux into the esophageal tube as a result of stomach contractions.Actually GERD can be attributed primarily to transient relaxation of thelower esophageal sphincter. In other cases, GERD can be attributed todecreased resting tone of the lower esophageal sphincter or tocongenital small dimension of the sphincter itself. Other causes alsoexist which contribute to varying degrees to the existence and severityof this disease.

In addition, there are external factors that contribute to exacerbatethe symptoms of GERD, which conditions include eating fatty foods,caffeine intake, smoking, tight clothing and certain medications.Decrease in salivation can also be a factor that exacerbates GERD, sinceunder normal conditions saliva, which is an alkaline liquid, aids inneutralizing acidic reflux and therefore diminishing the duration of theacidic exposure of the esophagus.

Erythema is one of the first visible signs of GERD, which can be seen byendoscopy. Tissue erosion indicates more advanced disease which can thenbecome deep ulcers and lead to cancer (adenocarcinoma increases inincidence faster than other types of cancer). Diffuse ulceration andspecific complications occur in about 3.5% of patients less than 65years of age with esophageal obstruction, blood loss, and in some cases,perforation.

Ulcerative situations not only lead to complications, but they are alsomore resistant to treatments. Although severe complications are uncommonin young patients, they occur in about 20-30% of patients over 65(Reynolds J. C., Am. J. Health-Sys. Pharm 53 (1996)).

At present, GERD is generally managed by over-the-counter (“OTC”)antacids or prescription drugs, including proton pump inhibitors,motility agents and H₂ blockers. In addition, a portion of GERD patientsrequire surgical intervention; the most common type of surgery isfundoplication which can be done by conventional surgical techniques, orusing laparoscopic techniques. However, fundoplication surgery carriesthe risk of serious side effects and is only marginally successful incuring GERD. Respiratory symptoms are also associated with GERD in about50% of patients, and in patients undergoing fundoplication, theserespiratory symptoms can even increase (76% reported in a study byJohnson W. E. et al., Archives of Surgery, 131:489-492 (1996)).

2.2 Urinary Incontinence and Urinary Reflux Disease

Urinary incontinence is a prevalent problem that affects people of allages and levels of physical health, both in the community at large andin healthcare settings.

Medically, urinary incontinence predisposes a patient to urinary tractinfections, pressure ulcers, perineal rashes, and urosepsis. Sociallyand psychologically, urinary incontinence is associated withembarrassment, social stigmatization, depression, and especially for theelderly, an increased risk of institutionalization (Herzo et al., Ann.Rev. Gerontal. Geriatrics, 9:74 (1989)). Economically, the costs areastounding; in the United States alone, over ten billion dollars peryear is spent managing incontinence.

Incontinence can be attributed to genuine urinary stress (urethrahypemobility), to intrinsic sphincter deficiency (“ISD”), or both. It isespecially prevalent in women, and to a lesser extent incontinence ispresent in children (in particular, ISD), and in men following radicalprostatectomy.

One approach for treatment of urinary incontinence involvesadministration of drugs with bladder relaxant properties, withanticholinergic medications representing the mainstay of such drugs. Forexample, anticholinergics such as propantheline bromide, and combinationsmooth muscle relaxant/anticholinergics such as racemic oxybutynin anddicyclomin, have been used to treat urge incontinence. (See, e.g., A. J.Wein, Urol. Cli N. Am., 22:557 (1995)). Often, however, such drugtherapies do not achieve complete success with all classes ofincontinent patients, and often results in the patient experiencingsignificant side effects.

Besides drug therapies, other options used by the skilled artisan priorto the present invention include the use of artificial sphincters (LimaS. V. C. et al., J. Urology, 156:622-624 (1996), Levesque P. E. et al.,J. Urology, 156:625-628 (1996)), bladder neck support prosthesis (KondoA. et al., J. Urology, 157:824-827 (1996)), injection of crosslinkedcollagen (Berman C. J. et al., J. Urology, 157:122-124 (1997), Perez L.M. et al., Urology, 1:633-636 (1996); Leonard M. P. et al., J. Urology,156:637-640 (1996)), and injection of polytetrafluoroethylene (Perez L.M. et al., J. Urology, 156:633-636 (1996)).

A recent well known approach for the treatment of urinary incontinenceassociated with ISD is to subject the patient to periurethral endoscopiccollagen injections. This augments the bladder muscle in an effort toreduce the likelihood of bladder leakage or stress incontinence.

Existing solutions to circumvent incontinence have well known drawbacks.The use of artificial sphincters for children with intractableincontinence requires long term surveillance of the urinary tractbecause of the potential for renal failure after device placement(Levesque P. E. et al., J. Urology, 156:625-628 (1996)). Whileendoscopically directed injections of collagen around the bladder neckhas a quite high success rate in sphincter deficiency with nosignificant morbidity, the use of collagen can result in failures thatoccur after an average of two years and considerations need to be givento its cost effectiveness (Khullar V. et al., British J. Obstetrics &Gynecology, 104:96-99 (1996)). In addition, deterioration of patientcontinency, probably due to the migration phenomena (Perez L. M. et al.)may require repeated injections in order to restore continency(Herschorn S. et al., J. Urology, 156:1305-1309 (1996)).

The results with using collagen following radical prostatectomy for thetreatment of stress urinary incontinence have also been generallydisappointing (Klutke C. G. et al., J. Urology, 156:1703-1706 (1996)).Moreover, one study provides evidence that the injection of bovinedermal collagen produced specific antibodies of IgG and IgA class.(McCelland, M. and Delustro, F., J. Urology 155, 2068-2073 (1996)).Thus, possible patient sensitization to the collagen could be expectedover the time.

Despite of the limited success rate, transurethral collagen injectiontherapy remains an acceptable treatment for intrinsic sphincterdeficiency, due to the lack other suitable alternatives.

Urinary reflux disease, or “vesicoureteral reflux” in its medical term,simply means that urine goes backwards in the ureters during urination.The disease often occurs in young children. The ureter is the tube whichconnects the kidneys with the bladder. Urine is supposed to go in onedirection: from the kidneys to the bladder. When urine goes up from thebladder to the kidneys, it can result in health problems for the person.

Urinary reflux can lead to kidney damage. Refluxing urine can carrybacteria to the kidney, where it can cause kidney infection. Childrenwith reflux of urine are much more likely to have kidney infection thanchildren who do not have reflux. The combination of reflux and infectioncan lead to areas of permanent kidney damage or “renal scarring.” Thisscarring is detected by doing an X-ray called an intravenous pyelogram(IVP), or preferably, a renal scan. If it is extensive enough, thescarring can lead to loss of function of one or both kidneys.

The key to preventing renal scarring is preventing kidney infections.This is currently being carried out in two ways. In most cases, longterm prophylactic antibiotics are given. The other method of preventingurinary tract infections is surgical correction of the reflux. Bothmethods, however, have drawbacks. Long term use of antibiotics may causeunpredictable side effects and surgical procedures involve unnecessaryrisks.

Even though many urinary reflux disease will go away on its own inchildren, some cases often lead to severe kidney and urinary tractinfections and even total kidney failure. There is a need, therefore,for a safe, effective, less intrusive, and long lasting method oftreating urinary reflux disease.

2.3 Tissue Bulking

Prior to the present invention, tissue bulking has been used for thetreatment of GERD and urinary incontinence. In an attempt to increasethe function of the sphincter, bulking methods using liquid orsemi-liquid preparation, such as collagen; rigid and non-deformableparticles, such as carbon particles; and injectable deformableparticles, such as Teflon® paste have been used in patients. Thesemethods have been generally unsuccessful, however, as they presentvarious drawbacks.

Tissue bulking agents are either biologically derived or synthetical andare designed to be injected or implanted in or near the sphincter orbladder neck to increase tissue bulk effect. While bulking proceduresare gaining acceptance, biologically-derived bulking agents may beabsorbed by the body, requiring repeated treatments. Consequently, theyare not considered the definitive treatment for GERD, urinaryincontinence, or urinary reflux disease. In addition, physicians haveexperienced problems with currently available synthetic agents,including movement of the synthetic agents to other non-affected partsof the body causing adverse health effects, incompatibility of thesynthetic agents with the human body, and difficulty in injecting theagents into the blood vessels or insufficient mechanical resistance.

Liquid or semi-liquid preparations with various degrees of viscosityhave been used for tissue bulking. The best known example is a collagenpreparation manufactured by Collagen Corporation (now part of (named)and marketed by C. R. Bard. These preparations are easily injectable,but they have one or more of the following limitations: (1) the collagenis gradually displaced within the tissue in which it was originallyinjected, thereby reduce or eliminating the intended bulking effect; (2)the collagen is digested biologically, through macrophages, or throughthe lymphatic system; and (3) the collagen tends to form a continuousforeign mass within the sphincter after injection thereof.

Solid rigid non-deformable particles, such as carbon particles, havealso been used for tissue bulking. These particles or preparations,however, are either too fragile or too large to be injected, or toosmall and are digested. Therefore, they all have one or more of thefollowing limitations: (1) the particles are too large to be injectedthrough needles of 18 to 26 gauge, thus limiting their applicability andeffectiveness in many tissuing bulking cases; (2) it is difficult toinject the particles through needles of 18 to 26 gauge because theirirregular shapes make them clamp together; (3) the particles are fragileso that they break during injection and the fragments are digested; (4)the injected particles are too small and are digested by the lymphaticsystem; and (5) the injected particles are displaced as they do notadhere to the surrounding cells at the site of injection.

Injectable deformable particles, such as Teflon® particles, have alsobeen used for tissue bulking. However, Teflon® particles have one ormore of the following limitations: (1) the particles slide with thetissue and do not stay in place of injection; (2) the particles deformduring and after injection, reducing the intended tissue bulking effect;and (3) the particles are digested or eliminated by the lymphatic systempartly due to the fact that their diameters become smaller as a resultof injection.

Therefore, there is a great need for safe, biocompatible, stable andeffective methods of tissue bulking for the treatment of various tissuedefects, particularly for the treatment of GERD, urinary incontinence,and urinary reflux disease. There is also a need for stable andbiocompatible injectable composition for tissue bulking.

3. SUMMARY OF THE INVENTION

The present invention provides injectable compositions comprisingswellable microspheres and method of using the injectable compositionsto perform tissue bulking, particularly for treatment of GERD, urinaryincontinence, and urinary reflux disease in a mammal. The composition isinjectable through 18 to 26 gauge needles and the microspheres are notcapable of being eliminated by macrophage (digested) or other elementsof said mammal's immune or lymphatic system after injection.

The microspheres of the present invention are highly water absorbing andcapable of swelling to many times of their original sizes under certainconditions. The microspheres of the present invention generally comprisecrosslinked polymers. Preferably, the microspheres comprise sodiumacrylate polymer, acrylamide polymer, acrylamide derivative polymer orcopolymer, sodium acrylate and vinyl alcohol copolymer, vinyl acetateand acrylic acid ester copolymer, vinyl acetate and methyl maleatecopolymer, isobutylene maleic anhydride crosslinked copolymer,starch-acrylonitrile graft copolymer, crosslinked sodium polyacrylatepolymer, crosslinked polyethylene oxide, or mixtures thereof. Thesemicrospheres are capable of swelling upon contacting with mediumresembling the properties of physiological fluids, thus allowing themicrospheres to secure themselves into position after injection into thebody. Furthermore, the microspheres are substantially spherical and canbe calibrated so that their sizes can be accurately determined. Themicrospheres of the invention have diameters from about 10 to about 500μm before swelling. Preferably, before swelling, the diameters of themicrospheres are from about 10 to about 300 μm and, most preferably,from about 100 to about 300 μm. After injection and swelling, themicrospheres have average diameters larger than about 40 μm, preferablylarger than about 70 μm and, more preferably, larger than about 100 μm.

In a preferred embodiment of the present invention, the microspheresfurther comprise cell adhesion promoters or cells on at least a portionof their surfaces. The cells are preferably autologous cells from thesubject mammal. Most preferably, the cells are autologous cells from thesame type of tissues being treated, such as fat cells, muscle cells,subcutaneous cells, dermal cells, and epidermal cells.

The microspheres of the present invention may further comprise atherapeutic or prophylactic agent, radio-pacifying agent, contrast agentor other detectable substances, targeting agent, or mixtures thereof,providing therapeutic and other benefits to the skin in addition totissue bulking.

In a preferred embodiment, the composition of the present inventioncomprises the microspheres in an amount ranges from about 10% to about90% by weight and the biocompatible carrier from about 10% to about 90%by weight. Preferably, the injectable composition is a suspension of themicrospheres in the biocompatible carrier. The biocompatible carrier ofthe present invention is preferably a solvent in which the microspheresare suspended. The solvent is preferably in such a condition that themicrospheres can be uniformly suspended and, more importantly, that theswelling of the microspheres are also controlled by adjusting thesolvent, the salt and ionic concentration, the pH value, or combinationsthereof. Suitable solvents for the present invention include aqueousbased solutions such as saline solutions, PBS solutions, alcohol basedsolutions, and other biocompatible hydro-organic solutions known in theart.

The microspheres of the present invention are capable of swelling uponcontact with physiological fluids, including blood, and cells andtissues at the injection site. The degree of swelling depends on factorssuch as the material of the microspheres and the degree of crosslinking,the solvent in which the microspheres were suspended before injection,and the biological and physiological conditions at the site ofinjection. Therefore, knowing the site of injection and its biologicaland physiological conditions will allow control of the degree ofswelling of the microspheres after injection by selecting the materialfor microspheres and the solvent in which they are suspended.

In a preferred embodiment, there is no aggregation or clumping of themicrospheres in the injectable composition before and during injection.The injectable composition of the invention further comprises a celladhesion promoter, cells or both associated with the microspheres,including on the surface of the microspheres. In addition, theinjectable composition can contain one or more of a therapeutic orprophylactic agent, radiopacifying agent, and contrast agent or mediumor other detectable substances to provide therapeutic and other benefitswhile performing tissue bulking.

The present invention additionally provides methods of tissue bulkingand treatment of GERD, urinary incontinence, and urinary reflux disease.Specifically, the invention provides a method of causing tissue bulkingin a mammal by administering swellable, hydrophilic, substantially andnon-toxic spherical microspheres in a biocompatible carrier to themammal. The composition is injectable through a needle of about 18 to 26gauge, preferably about 22 to 24 gauge, and the microspheres are notcapable of being digested or eliminated by the lymphatic or immunesystem.

According to the present invention, a preferred method of administrationis injecting the composition into an area of the mammal that is in needof tissue bulking. The tissue bulking method of the present invention isespecially suitable for the treatment of GERD, urinary incontinence, andurinary reflux disease. A preferred method of administration isinjecting the composition into the walls of the sphincter for treatmentof GERD and into the bladder sphincter or the urethra for the treatmentof urinary incontinence and urinary reflux disease.

The present invention further provides a method of causing tissuebulking by administering the injectable suspension extracorporeally intoorgans, components of organs, or tissues prior to the inclusion of saidorgans, or components of organs into body.

The present invention additionally provides a kit for performing tissuebulking. The tissue bulking kit of the present invention comprises an 18to 26 gauge needle and a corresponding syringe, wherein the syringecontains a composition comprising biocompatible, swellable, hydrophilic,non-toxic and substantially spherical microspheres and a biocompatiblecarrier. The composition is injectable through the needle and themicrospheres are not capable of being digested or eliminated bymacrophage or other elements of said mammal's immune system.Alternatively, the syringe does not contain a solution or suspension butis accompanied by (a) dry microspheres which are ready for preparationof a suspension; (b) a preformed solution or suspension of microspheres;or (c) dry microspheres and a biocompatible solution in separatecontainers.

4. DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a safe, effective, stable, and longlasting method of tissue bulking, which method is useful for thetreatment of a variety of tissue defects. The method is particularlyuseful for the treatment of Gastro-esophageal reflux disease, urinaryincontinence, and urinary reflux disease. The invention encompassesinjectable compositions comprising biocompatible, swellable,hydrophilic, non-toxic and substantially spherical microspheres and abiocompatible carrier. The invention further provides methods of tissuebulking by administrating the injectable composition to a mammal in needof treatment for various tissue defects, particularly, Gastro-esophagealreflux disease, urinary incontinence, or urinary reflux disease. Theinjectable compositions and methods of tissue bulking of the presentinvention are believed to have the following advantages: (1) theinjected materials are not easily displaced within the tissues in whichthey were originally injected, thus the intended tissue bulking effectis achieved without repeated administration or causing adverse effectsto the patient, (2) the injected materials are not readily digested,displaced, or eliminated either biochemically or through the lymphaticsystem, thus the method is effective and long lasting, (3) the materialsare of sufficient size to be injected through 18 to 26 gauge needles,thus the method is accurate, efficacious and less intrusive to thepatient, (4) the injected particles are not fragile, facilitating easyinjection without being broken, thus providing easy and safe injection,and, preferably, (5) the injected particles are not irregularly shapedand do not clump together, also providing easy and accurate injection.These benefits, whether alone or in combinations, enhance theeffectiveness of the treatment and are safe, convenient and comfortablefor patients.

As used in the present invention, “microspheres” means polymer orcombinations of polymers made into bodies of various sizes. Themicrospheres can be in any shape, although they are often insubstantially spherical shape. Further, as part of the injectablecomposition of the present invention, the microspheres are alsosterilized before injection.

“Swellable” microspheres, as used in the present invention, refers tomicrospheres that are capable of being enlarged in size, yet stillretain substantially the same shape, upon certain conditions such ascontacting physiological fluids. Preferably, the swellable microspheresof the present invention can be enlarged to about 15 times of theiroriginal sizes. The degree of swelling can be controlled by controllingfactors such as the solvents in which they are suspended, specificpolymers used to make the microspheres and degree of crosslinking. Thisproperty enables the microspheres to be injected through needles of 18to 26 gauge, yet be enlarged and secured at the injection site and ofsufficient size to avoid or reduce the chance of being eliminated by thelymphatic or immune system of the mammal.

“High water absorbing polymers” as used in the present invention refersto polymers that can absorb at least 5% of water by weight or that arecapable of increasing their dry weight to about 20 times of theiroriginal weight.

“Biodegradable” microspheres refer to microspheres that are capable ofbeing absorbed by the body, chemically, physiologically, or by otherbiological means, over a period of time.

The microspheres of the present invention also comprise particles thatare “hydrophilic,” which, as used in the invention, means the particlescan dissolve in, absorb, or mix easily with water or aqueous solution.

“Substantially spherical” generally means a shape that is close to aperfect sphere, which is defined as a volume that presents the lowestexternal surface area. Specifically, “substantially spherical” in thepresent invention means, when viewing any cross-section of the particle,the difference between the average major diameter and the average minordiameter is less than 20%. The surfaces of the microspheres of thepresent invention appear smooth under magnification of up to 1000 times.The microspheres of the present invention may comprise, in addition tothe particles, other materials as described and defined herein.

“Tissue bulking” in the context of the present invention refers to anychange of the natural state of a mammal's non-dermal tissues due toexternal acts or effects. The tissues encompassed by the inventioninclude, but not limited to, muscle tissues, connective tissues, fats,and, nerve tissues. The tissues encompassed by the present invention maybe part of many organs or body parts including, but not limited to, thesphincter, the bladder sphincter and urethra.

“Injectable” as used in the present invention means capable of beingadministered, delivered or carried into the body via syringe, catheters,needles or other means for injecting or infusing microspheres in aliquid medium.

“Cell adhesion promoter” in the present invention means any materialthat, because of their presence in or association with the microspheres,promotes or enhances the adhesiveness of cells to the surface of themicrospheres. These materials are often proteins that are bound to thesurface of the microspheres through covalent bonds of the proteins andthe polymers.

“Therapeutic agent” in the present invention refers to any substancethat provides therapeutic effects to the process of tissue bulking orbiological or physiological responses to the tissue bulking. An exampleof therapeutic agent is an anti-inflammation agent that prevents orreduce the effect of inflammations associated dermal augmentation.

“Chemical modification” in the present invention means the changes ofchemical properties and characteristics of the microspheres, eitherduring their production process or by way of mixing or contacting themwith various agents or tissues, such that the microspheres have theability to perform, in addition to tissue bulking, other functions onceinjected into the body.

For clarity of disclosure, and not by way of limitation, the detaileddescription of the present invention is divided into the subsectionswhich follow.

4.1 Microspheres

Microspheres for use in the present invention are based on non-toxic,biocompatible, swellable, hydrophilic, and substantially sphericalparticles which comprise various polymers. The microspheres of thepresent invention comprise crosslinked polymers that are high waterabsorbing and, thus, capable of swelling upon contacting with aqueousmedium in certain conditions. As understood by a person skilled in theart, the degree of swelling of crosslinked polymers generally depends onthe properties of the polymeric materials such as their ionic character,the hydrophilicity of the polymeric materials, and the degree ofcrosslinking. Properties, such as salt and ionic concentration and levelof pH, of the solvent in which the microspheres are suspended or withwhich the microspheres are contacting also affect the degree ofswelling.

As disclosed herein, by controlling the size and the degree of swellingof certain crosslinked and swellable polymers, safe, effective, and longlasting tissue bulking can be achieved using these microspheres.According to the invention, polymeric materials having high waterabsorbing ability are first chosen. The swellability of these polymerscan be further manipulated by controlling the polymer's ionic characterand the degree of crosslinking by methods known to a skilled artisan.

The microspheres of the present invention can be either anionic orcationic. Preferably, cationic microspheres are used because of theirsuperior ability of promoting cell adhesion. The crosslinking degree ofthe microspheres can be changed either chemically or through radiation.A variety of crosslinking agents may be used, including, but not limitedto, tetraethylene glycol diacrylate, tetraethylene glycoldimethacrylate, ethylene glycol dimethacrylate, methacrylate, andpentaerythritol dimethacrylate. The microspheres of the invention maycomprise from about 0.5% to about 20%, by molecular weight, ofcrosslinkers. Preferably, the microspheres comprise from about 1% toabout 5%, by molecular weight, of crosslinkers.

More importantly, the present invention has discovered that the swellingof the microspheres comprising these polymers can be further controlledby controlling the solvent in which the microspheres are suspended. Thisis achieved through two steps as disclosed herein. First, the size ofthe microspheres before injection are controlled by using appropriatesolvents, salt concentration and pH level according to the specificmicrospheres used. The microspheres before injection may either remainin their original size or swell to certain degree due to their contactwith the solvent. The pre-injection swelling is controlled so that themicrospheres are injectable through 18 to 26 gauge needles. Second,after injection and upon contacting with tissues at injection site, themicrospheres may further swell into predetermined size or retain theirpre-injection size, either of which size will allow the microspheres tobe secured at the site of injection and achieve desired tissue bulkingeffect. The degree of pre-injection swelling, and thus the afterinjection swelling, is determined by the particular microspheres usedand the nature and location of the tissue defects being treated.

Microspheres for use in the present invention have diameters range fromabout 10 to about 500 μm before swelling. Preferably, before swelling,the diameters of the microspheres are from about 10 to about 300 μm and,most preferably, from about 100 to about 300 μm. After injection andswelling, the microspheres have average diameters larger than about 40μm, preferably larger than about 70 μm and, more preferably, larger thanabout 100 μm. The microspheres of the present invention are capable ofswelling to about 4 times of their original diameters or about 15 timesof their original volume. The full swollen size of the microspheresafter injection are controlled, by various means discussed above, sothat they are secured at the site of injection while not causing anypotential injuries to the tissues. Further, the full swollen sizes ofthe microspheres after injection are predetermined based on factors suchas the physiological conditions of the injection site, the originalmicrospheres sizes, the solvent used and the pre-injection swelling ofthe microspheres. Thus, a specific injection plan can be designedaccording to the particular tissue bulking need of the case. These sizesand properties of the microspheres are advantageous in that they enablethe microspheres to be easily injectable through needles of 18 to 26gauge, preferably 22 to 24 gauge, yet the microspheres are large enoughso that they will be secured at the site of injection and will not bedigested or eliminated by macrophage or other elements of the immune orlymphatic system.

The microspheres are also resistant to injection force created by 18 to26 gauge needles and to the muscle contraction stress generated duringand after the injection process. The microspheres are also thermallystable which allows for easy, convenient sterilization, and frozenstorage for the preparation of injection.

Many types of crosslinked polymers having high water absorbing abilityare suitable for use in the present invention as long as they arenon-toxic to tissues and cells and are biocompatible. Preferably, thepolymers are selected from the group consisting of sodium acrylatepolymer, acrylamide polymers, acrylamide derivative polymers orcopolymers, sodium acrylate and vinyl alcohol copolymer, saponificationproducts of copolymer of vinyl acetate and acrylic acid ester, vinylacetate and acrylic acid ester copolymer, vinyl acetate and methylmaleate copolymer, isobutylene-maleic anhydride crosslinked copolymer,starch-acrylonitrile graft copolymer and its saponification products,crosslinked sodium polyacrylate polymer, and crosslinked polyethyleneoxide.

The microspheres of the present invention can be biodegradable ornon-biodegradable. Preferably, the microspheres of the invention aresterilized before injection. They are also thermally stable which allowsfor easy, convenient sterilization, and frozen storage. The microspheresfor use in the present invention are also stable in suspension whichallows the microparticles to be formulated and stored in suspension andinjected with different liquids or oils. More specifically, thehydrophilic nature of the microspheres permits placing them insuspension, and in particular, in sterile form of injectable solutions,while avoiding the formation of aggregates or adhesion to the walls ofstorage containers and implantation devices, such as catheters,syringes, needles, and the like.

The microspheres of the present invention may contain within theirstructure or on their surfaces other chemicals, therefore displayingparticular properties, such as therapeutic, radio-pacifying, andcontrasting effects; promotion of cell adhesion; and capability of beingchemically modified.

The microspheres of the present invention may further associated withcontrast medium or agent. Contrast media useful within the presentinvention can be found in Dawson et al. Contrast Medium in Practice(Springer-Verlag, 1994). Contrast media include, but not limited to,ultrasonic media, superparamagnetic media, and gadolinium contrastmedia. Preferably, the contrast media are any media that contain bariumor iodine salts, such as high molecular weight salts, includingacylamino-e-propion-amido-3-triiodo-2,4,6-benzoic acid, which can beprepared under the conditions described by Boschetti et al. (Bull. Soc.Chim., No. 4 France, (1986)). In the case of barium or magnetite salts,they can be directly introduced in powered form in the initial monomersolution.

In another embodiment of the invention, the microspheres have specificproperties suitable for cell adhesion and cells growth promotion, makingthe microspheres particularly useful for certain tissue bulkingprocedures. Cells are associated with the microspheres, through adhesionor other means, prior to injection. Preferably, the cells are autologouscells from the subject mammal. These autologous cells are preferably thesame type of cells that need to be repaired in the tissue bulkingprocedure, such as fat cells, muscle cells, subcutaneous cells, dermalcells, epidermal cells, connective tissue cells, or combinationsthereof. The autologous cells may also preferably be cells that enhanceor promote the growth or connection of cells or tissues, such asfibroblast.

Various types of cell adhesion promoters well known in the art may beused in the present invention. In particular, cell adhesion promoterscan be selected from collagen, gelatin, glucosaminoglycans,fibronectins, lectins, polycations (such polylysine, chitosan and thelike), extracellular matrix, degradation products of cells or tissues,or any other natural or synthetic biological cell adhesion agent.

Cell adhesion promoters or marking agents are introduced on microspheresby chemical coupling procedures well known in affinity chromatography,referred to by the term “ligand immobilization”. Another method ofintroduction is by diffusion within the gel network that constitutes thebead and then trapping the diffused molecules in place by precipitationor chemical cross-linking. Therapeutic agents, drugs or any other activemolecules that are suitable for transportation by the beads can also beintroduced into the microspheres prior to injection.

The microspheres of the present invention also can be chemicallymodified so that they will “carry” therapeutic effects, vascularizationeffects, anti-vascularization effects, visualization properties,anti-inflammatory effects, anti-bacterial effects, anti-histamineeffects, or combinations thereof. The chemical modification of themicrospheres of the present invention is made possible by the fact thatthe microspheres comprise particles made of polymers that arecrosslinked so that they can contain chemicals within their structuresthat possess various properties and that they possess uniquecharacteristics associated with surface covalent bonds.

Incorporation of active molecules, such as drugs, into the microspheresof the present invention can be accomplished by mixing dry microsphereswith solutions of said active molecules or drugs in an aqueous orhydro-organic solution. The microspheres swell by adsorbing thesolutions and incorporate the active molecule of interest into themicrosphere network. The active molecules will remain inside themicrosphere due to an active mechanism of adsorption essentially basedon ion exchange effect. The microspheres by their nature carry cationicgroups and have the ability to adsorb anionic molecules, such as wellknown anti-inflammatory drugs, and these anionic molecules are thenreleased slowly upon injection into the patient due to the action ofphysiological salt and pH. The ability of various types of microspheresto adsorb drug molecules may be readily determined by the skilledartisan, and is dependent on the amount of cationic monomers present inthe initial solution from which the microspheres are prepared.

Microspheres of the present invention further possess the property ofnon-aggregating, which usually results from an ionic charge of themicrospheres. This allows easier injection and more effective tissuebulking, especially in situations where cells are associated with themicrospheres. This property is important to tissue bulking of thepresent invention because it makes injection of the microspheres through18 to 26 gauge needles possible and easier. This property of themicrospheres also prevents them from aggregating or adhering to syringeor needle walls or other device used in the process.

The microspheres of the invention can be obtained by standard methods ofpolymerization described in the art such as French Patent 2,378,808 andU.S. Pat. Nos. 5,648,100 and 5,635,215 each of which is incorporatedherein by reference. In general, the polymerization of monomers insolution is carried out at a temperature ranging between about 0° C. andabout 100° C. and between about 40° C. and about 60° C., in the presenceof a polymerization reaction initiator.

Microspheres of the present invention can also be prepared by suspensionpolymerization, drop-by-drop polymerization or any other method known tothe skilled artisan. The mode of microsphere preparation selected willusually depend upon the desired characteristics, such as microspherediameter and chemical composition, for the resulting microspheres. Themicrospheres of the present invention can further be made by methods ofpolymerization described in the art (see, e.g., E. Boschetti,Microspheres for Biochromatography and Biomedical Applications. Part I,Preparation of Microbeads In: Microspheres Microencapsulation andLiposomes, John Wiley & Sons, Arshady R., Ed., 2:171-189 (1999), whichis incorporated herein by reference). Microspheres can also be preparedstarting from an aqueous solution of monomers containing adhesion agentssuch as collagen (gelatin is a denatured collagen). The solution is thenmixed with a non-aqueous-compatible solvent to create a suspension ofdroplets, which are then turned into solid gel by polymerization ofmonomers by means of appropriate catalysts. Microspheres are thencollected by filtration or centrifugation and washed.

4.2 Injectable Composition

The present invention provides an injectable composition suitable fortissue bulking. Specifically, the suspension comprises biocompatible,swellable, hydrophilic, non-toxic, and substantially sphericalmicrospheres and a biocompatible carrier. The composition is injectablethrough needles of about 18 to 26 gauge, preferably about 22 to 24gauge, and said microspheres are not capable of being digested oreliminated by macrophage or other elements of said mammal's immune orlymphatic system.

The various specific and preferred embodiments for microspheresdescribed in §4.1 can be used in the injectable composition.

The injectable suspension of the present invention preferably comprisescells. The cells are preferably associated with the microspheres. Morepreferably, the cells are autologous cells from the subject mammal.These autologous cells are preferably the same type of cells that needto be repaired in the tissue bulking procedure, such as fat cells,muscle cells, subcutaneous cells, dermal cells, epidermal cells,connective tissue cells, or combinations thereof. The autologous cellsmay also preferably be cells that enhance or promote the growth orconnection of cells or tissues, such as fibroblast.

Many types of emulsion and solvents can be used as the biocompatiblecarrier for the injectable composition. The solvent is preferably insuch a condition that the microspheres can be uniformly suspended and,more importantly, that the swelling of the microspheres are alsocontrolled by adjusting the solvent, the salt and ionic concentration,the pH value, or combinations thereof. Suitable solvents for the presentinvention include aqueous based solutions such as saline solutions, PBSsolutions, alcohol based solutions, and other biocompatiblehydro-organic solutions known in the art.

Salt concentration and pH level of the solvent are important incontrolling the degree of swelling of the microspheres once they aresuspended in the solvent. The presence of cations such as sodium,potassium, calcium, magnesium, iron, zinc, and ammonium has variouslevel of effects on the degree of swelling of the microspheres dependingon the specific polymer and salt used. The degree of swelling of themicrospheres is partially controllable by changing the balance ofsmaller cations and larger cations between the solvent and themicrospheres. In a preferred embodiment, the contrasting agentassociated with the microspheres serves as an agent controlling thedegree of swelling of the microspheres. A salt level of 0.01 M to 5 M iseffective to keep the microspheres from swelling. While the microspheresswell uninhibitedly under a neutral pH level, the change of pH levelwill affect the degree of swelling. For the anionic microspheres, thepreferred pH level to shrink the microspheres or to keep them fromswelling is from about 0.1 to 5. For the cationic microspheres, a pHlevel ranges from about 6 to about 11 will shrink the microspheres orkeep them from swelling.

Upon suspension in the solvent and before injection, the microspheresmay swell and the degree of swelling is controlled by the solvent andother conditions, such as time and temperature of suspension. Thepre-injection swelling of the microspheres is further determined by thedesired after-injection-swelling for the microspheres. Thus,microspheres that have obtained high degree of swelling before injectionwill swell little after injection, whereas microspheres that haveswelled little before injection will obtain a higher degree of swellingafter injection. The size of the microspheres before, during and afterinjection is always controlled such that they are easily injectablethrough 18 to 26 gauge needles yet become secured at the site ofinjection.

The biocompatible carrier of the present invention can also be anemulsion. In this embodiment, the properties of the microspheres,especially their size and degree of swelling, are preserved through thewell controlled balance between the aqueous and the non-aqueous phasesin the emulsion.

Preferably, the injectable composition of the present invention comprisethe microspheres in an amount from about 10% to about 90% by weight andthe biocompatible carrier in an amount from about 10% to about 90% byweight. More preferably, the amount ranges from 10% to 50% by weight formicrospheres and from 50% to 90% for biocompatible carrier. The relativeamount of the microspheres and the carrier changes according to the needof the specific tissue bulking performed, depending on factors such assize of needle used, type of microspheres and carriers used, type ofskin deficiency, area of injection, type of tissue or cells beingbulked, and whether cells are associated with the microspheres prior toinjection.

To prepare a suspension of the microspheres, dried sterilizedmicrospheres are mixed with the desired solvent at a pre-determined timesuch that the pre-injection swelling of the microspheres is controlled.The solvent can be pre-sterilized or the suspension of microspheres andthe solvent can be sterilized together before injection thereof. Factorssuch as the material, size and crosslinking degree of the microspheres;the type, volume, salt concentration, pH level and temperature of thesolvent; and the time of mixing are all considered before an injectablesuspension is made and the injection is carried out thereafter.

The composition of the present invention is easily injectable, throughneedles of 18 to 26 gauge, preferably, 22 to 24 gauge, into all parts ofthe mammal in need of treatment without causing significant pain ordiscomfort. This is due to, among other factors, the size and thephysical resiliency of the microspheres, the biocompatible nature of thecarrier, and the amount of the composition administered in accordancewith the character and location of the tissue defects.

4.3 Method of Tissue Bulking

The present invention further provides methods of causing tissuebulking. The methods comprise administering a composition ofbiocompatible, swellable, hydrophilic, non-toxic and substantiallyspherical microspheres in a biocompatible carrier to a mammal. Themethod further specifies that the suspension is injectable through aneedle of about 18 to 26 gauge, preferably about 22 to 24 gauge, and themicrospheres are not capable of being digested, displaced, or eliminatedby the mammal's lymphatic or immune system.

The various specific and preferred embodiments of the injectablecompositions described in §§4.1 and 4.2 can be used in the method fortissue bulking.

The tissue bulking method of the present invention is suitable for thetreatment of various tissue defects, such as defects in dental tissues,vocal cord tissues, and other non-dermal soft tissues. The presentmethod is particularly suitable for the treatment of Gastro-esophagealreflux disease, urinary incontinence, and urinary reflux disease. Themethod reduces or eliminates immunological response and the rejection ofthe microspheres. The injection method of the present invention can becarried out by syringes, catheters, needles and other means forinjecting or infusing microspheres in a liquid medium. Further, the useof biocompatible, swellable, hydrophilic, non-toxic and substantiallyspherical microspheres and biocompatible carrier and, preferably,autologous cells, improves tissue acceptance and the effectiveness ofthe treatment. The methods of the invention also increase connectivetissue response.

In one embodiment, the tissue bulking methods of the present inventionare for the treatment of Gastro-esophageal reflux disease. Thistreatment is preferably carried out by injection of the injectablecomposition into the lower esophageal sphincter or the diaphragm of themammal in need of treatment. This injection can be facilitated by eitherendoscopic delivery or by laparoscopic technique. The injection ispreferably made into the walls of the sphincter where the esophagusmeets the stomach, i.e., the lower esophageal sphincter. This decreasesthe internal lumen of the sphincter muscle, thus permitting easiercontraction of the muscle with reduced regurgitation of the gastricfluids into the esophagus. Furthermore, when combined with the variousadvantageous embodiments of the injectable composition, such asautologous cells and therapeutic agents, the methods of the presentinvention provides additional and more beneficial therapeutic effects.

The primary advantages of the method of treating GERD according to thepresent invention over the prior art methods are:

a) Less invasive effects on the patient compared to surgery;

b) More accurate and effective delivery of the microspheres andtherapeutic agents;

c) More permanent effects over antacids or other drugs;

d) Good biocompatibility with chemotactic effects; and

e) Ability to use X-ray visualization or MRI to assist in follow-upevaluation of the patient.

In another embodiment of the present invention, the tissue bulkingmethod is for the treatment of urinary incontinence and urinary refluxdisease. This treatment is preferably carried out by injection of theinjectable composition into the bladder sphincter or the urethra of themammal. Treatment according to this method reduces the internal lumen ofthe sphincter muscle and the urethra muscle, thus permitting easiercontraction of the muscle with reduced likelihood of incontinence orurinary reflux. This also reduces the likelihood of bladder-neckhypermobility, which is often a cause for urinary incontinence andurinary reflux disease.

Some of the primary advantages of treating urinary incontinence orurinary reflux disease according to the present invention over prior artmethods are:

a) More permanent effect than the use of regular viscous solutions ofcollagen;

b) More accurate and effective delivery of the microspheres andtherapeutic agents;

c) Good biocompatibility with chemotactic effect;

d) Visualization under X-ray or MRI to assist in follow-up evaluation;and

e) Preventing repeated treatments with resorbable naturally occurringsubstances like collagen.

Injected microspheres can generate some transient adverse reactions suchas local inflammation, therefore the microspheres can contain or beinjected with anti-inflammatory drugs, such as salicylic acidderivatives including aspirin; para-aminophenol derivatives includingacetaminophen; non-steroidal anti-inflammatory agents includingindomethacin, sulindac, etodolac, tolmetin, diclodfenac, ketorolac,ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin;anthranilic acids including mefenamic acid, meclofenamic acid; enolicacids such as piroxicam, tenoxicam, phenylbutazone, oxyphenthatrarone;nabumetone; Vioxx® and Celebrex™ These anti-inflammatories arepreferably adsorbed on the microsphere's network and released slowlyover a short period of time (a few days). The microspheres may also beused to release other specific drugs which can be incorporated withinthe microsphere network before injection into the patient. The drugwould be released locally at the site of implantation over a shortperiod of time to improve the overall treatment.

The present invention further provides method of tissue bulking byinjecting the injectable composition not directly into the body, butextracorporeally into organs, components of organs, or tissues prior tothe inclusion of said tissues, organs or components of organs into thebody.

The frequency and the amount of injection under the present invention isdetermined based on the nature and location of the particular tissuedefect being treated. Generally, because of the stable and long lastingcharacter of the present invention's injectable composition, multipleinjections are not necessary. In certain cases, however, repeatedinjection may be necessary to achieve optimal results. A skilledpractitioner should be able to determine the frequency and the amount ofthe injection for each particular case.

According to the present invention's methods, after injection,microspheres become secured at the position of the injection. Themicrospheres are not digested or eliminated by macrophage or otherelements of the immune or lymphatic system. Furthermore, themicrospheres will not displace or slide away from the position ofinjection. The secure of the microspheres at the position of injectionis due to, among other factors, their size, physical resiliency, andhydrophilicity. The swellability of the microspheres at the site ofinjection is important in helping secure the microspheres at the site ofinjection. Upon contacting the physiological fluids and the cells at thesite of injection, the microspheres may further swell if there is nopre-injection swelling or the swelling is controlled to a lower level.The physiological condition, including salt concentration (e.g., sodiumand potassium) and pH level, may further help the microspheres swell tothe desired size.

This property of the microspheres allows precise control of theinjection and makes it possible that the microspheres work together atposition of injection and provide a scaffold for effective tissuebulking. In fact, the present invention has discovered that, because ofthe precision of the injection and the securing of the microspheres atthe site of injection provided by the invention, it is now possible tocreate a scaffold of microspheres at the site of injection withoutforming a scaffold of the microspheres before injection. The “injectablescaffold” of the present invention is especially advantageous over priorart in which surgical procedures are necessary in order to implant ascaffold for certain dermal augmentation. This discovery significantlyreduces the complexity of tissue bulking when a scaffold is desired formore effective dermal augmentation in certain cases. This uniquecontribution of the present invention to tissue bulking and thetreatment of GERD, urinary incontinence and urinary reflux disease ismade possible, in part, by the well controlled size and degree ofswelling of the microspheres, as discussed above. The ability of forminga scaffold at the injection site without forming a scaffold before theinjection makes the microspheres of the present invention particularlyeffective in providing tissue bulking. The size of the scaffold isdetermined by the amount and frequency of the injection, which is inturn determined by the nature and location of the tissue defects beingtreated. A skilled practitioner would appreciate the teaching of thepresent invention as a whole and be able to determine the exact amountand frequency of injection for each particular case.

The injection method of the present invention can be carried out by anytype of sterile needles of 18 to 26 gauge and corresponding syringes orother means for injection, such as a three-way syringe. The needles,syringes and other means for injection are commercially available fromsuppliers such as VWR Scientific Products (West Chester, Pa.), BectonDickinson, Kendal, and Baxter Healthcare. The size of the syringe andthe length of the needle used will dependent on the particular injectionbased on factors such as the specific disease or disorders beingtreated, the location and depth of the injection, and the volume andspecific composition of the injectable suspension being used. A skilledpractitioner will be able to make the selection of syringe and needlebased on experience and the teaching of the present invention.

The present invention additionally provides a kit for performing tissuebulking. The kit comprises an 18 to 26 gauge needle and a correspondingsyringe, wherein the syringe optionally contains a compositioncomprising biocompatible, swellable, hydrophilic, non-toxic andsubstantially spherical microspheres and a biocompatible carrier. Thecomposition is injectable through the needle and the microspheres arenot capable of being digested or eliminated by macrophage or otherelements of said mammal's immune system. Alternatively, the tissuebulking kit comprises a 18 to 26 gauge needle, a corresponding syringe,and separate containers containing the microspheres in dried form andthe biocompatible solvent. The dried sterilized microspheres and thesolvent are ready to be mixed for injection either in their respectivecontainers or in the syringe. These tissue bulking kits are sterile andready to use. The kits are designed in various forms based the sizes ofthe syringe and the needles and the volume of the injectable compositioncontained therein, which in turn are based on the specific tissuedefects the kits are designed to treat.

The invention is further defined by reference to the following examplesthat describe in detail the preparation of injectable composition andthe method of causing tissue bulking using the injectable composition.The following examples are illustrative only and should in no way limitthe scope of the present invention. It will be apparent to those skilledin the art that many modifications, both to materials and methods, maybe practiced without departing from the purpose and scope of thisinvention.

5. EXAMPLES Example 1

In a beaker containing 100 ml of demineralized water, 58 g of sodiumchloride and 27 g of sodium acetate are dissolved. One adds 400 ml ofglycerol and then the pH is adjusted between 5.9 and 6.1. Then 90 g ofN-tris-hydroxy-methyl methylacrylamide, 35 mg ofdiethylaminoethylacrylamide and 10 g of N,N-methylene-bis-acrylamide areadded. One heats at 60-70 C and 100 mo of a hot 300 mg/ml gelatinsolution is added. The total volume of the mixture is adjusted to 980 mlby addition of hot water and then 20 ml of a 70 mg/ml ammoniumpersulfate solution and 4 ml of N,N,N′,N′-tetramethylethylenediamine areadded.

This solution is poured into paraffin oil at 50-70 C stirring. After afew minutes, the polymerization reaction of acrylic monomers ismanifested by an increase of temperature. The microspheres are thenrecovered by decanting, washed carefully, screened and sterilized in anautoclave in a buffered medium.

Those microspheres, after screen calibration, possess thecharacteristics desired for tissue bulking, including a marked cationiccharge and an effective adhesion agent (gelatin or denatured collagen).

Example 2

The procedure of Example 1 is followed, using triethylaminoethylacrylamide instead of diethylaminoethyl acrylamide. After recovery ofthe spheres, the gelatin is reticulated by means of a 25% glutaraldehydesolution (100 ml of all of the microspheres).

The treatment is carried out stirring at 4 C overnight. It is followedby a washing with demineralized water.

Examples 3 and 4

The procedure of Examples 1 and 2 is followed, replacing 10 g ofN-tris-hydroxymethyl methylacrylamide with 10 g of acrylic acid. Themicrospheres obtained possess high swellability that is controlled bysalt and ionic concentration and pH level. Those microspheres areadvantageously usable in direct view of the user at the time ofhandling.

Examples 5 and 6

The procedure of Examples 1 and 2 is followed, replacingN-tris-hydroxymethyl methylacrylamide with 10 g of N-acryloylhexamethylene Procion Red HE-3B. The microspheres obtained possess anintense red coloration due to the integration of the acrylic dye in thepolymer lattice. Those microspheres are advantageously usable in directview of the user at the time of handling.

Examples 7 and 8

One hundred milliliters of microspheres obtained according to Examples 1to 4 are washed with a 0.1 M borate buffer of pH 8 and then suspended in50 ml of a 5 mg/ml rhodamine isothiocyanate solution. The suspension isthen stirred for at least 15 hours, after which it is washed with aneutral buffer to a colorless supernatant.

Those fluorescent red-colored microspheres are then calibrated andsterilized, and can be used in tissue bulking.

Examples 9 and 10

The procedure of Examples 1 to 4 is followed, replacing 10 g ofN-tris-hydroxymethyl methylacrylamide with 10 g of a monomer opaque toX-rays, (acrylamido-3-propionamido)-3-triiodo-2,4,6-benzoic acid.

The microspheres obtained possess the property of absorbing X-rays andare therefore of particular interest in their in vivo follow-up aftertissue bulking.

Examples 11 to 14

The procedure of Examples 1 to 2 is followed, adding to the initialmonomer solution 5 g of a radio-opaque soluble linear polymer,acrylamino-3-triiodo-2,4,6-benzoic polyacid (Examples 11 and 12) or(acrylamino-3-propionamido)-3-triiodo-2,4,6-benzoic polyacid (Examples13 and 14).

Those polymers, having a molecular weight exceeding 100,000 Dalton, areimprisoned in the polymer lattice and, without disturbing the generalproperties of the microspheres for the applications claimed, make itpossible to attain a radiopacity usable for the in vivo follow-up oftissue bulking procedure.

Examples 15 and 16

The procedure of Examples 1 and 2 is followed, adding to the initialmonomer solution 200 g of barium sulfate power. The microspheresobtained are opaque to both visible light and X-rays.

Examples 17 and 18

The procedure of Examples 1 and 2 is followed, adding 50 mg of magnetite(Fe3O4) to the initial monomer solution.

The microspheres obtained have the property of being detected in(Magnetic Resonance Imaging) MRI imagery.

Example 19 Comparative Evaluation of Two Types of Nonresorbable Spheres

The study consisted of injecting two types of calibrated microspheres,some prepared according to Example 2, the others of polystyrene(Biosilon Nunc Danemark), in pulmonary arterial vascularization of therat and of observing on days 0, 8 and 30 the extent of the cell reactionand the remodeling modalities of the occluded vessels.

The study revealed four important facts:

placement in suspension and vascular injection of the polystyrenespheres is difficult and clusters are formed at the segmental narrowingconstituting the nozzle of the syringe, the base of the catheter and thepossible changes of diameter of the catheters;

the cell reaction is earlier, more intense and more durable with thespheres of Example 1 than with polystyrene. On the 8th day the thicknessof the cell reaction covering the spheres of the invention is almostthree times greater than that covering the polystyrene spheres (34 μm ascompared to 13 μm);

there is no differences in kinetics in the vascular remodeling witheither material;

no phenomenon suggesting the toxicity of either material was observed.

In conclusion, the microspheres of the invention are more manageable andmore effective as adhesive agent.

Example 20 Preparation of Injectable Suspension

A suspension of 100 μm to 120 μm polyacrylamide copolymer microspheresin an oily contrast medium is prepared.

The embodiments of the present invention described above are intended tobe merely exemplary and those skilled in the art will recognize, or beable to ascertain using no more than routine experimentation, numerousequivalents to the specific procedures described herein. All suchequivalents are considered to be within the scope of the presentinvention and are covered by the following claims.

The contents of all references described herein are hereby incorporatedby reference. Other embodiments are within the following claims.

1. A method of treating urinary incontinence or urinary reflux disease, comprising: injecting a composition comprising substantially spherical microspheres in a biocompatible carrier to a bladder sphincter muscle or urethra muscle of a mammal; and reducing an internal lumen of the bladder sphincter muscle or urethra muscle with the composition as a tissue bulking agent, wherein the microspheres comprise at least one of an acrylamide polymer, acrylamide derivative polymer, an acrylamide derivative copolymer, or mixtures thereof.
 2. The method of claim 1, wherein the method of treating urinary incontinence or urinary reflux disease comprises treating at least one of bladder-neck hypermobility, urethra hypermobility, intrinsic sphincter deficiency, or vesicoureteral reflux.
 3. The method of claim 1, wherein the microspheres are biocompatible, swellable, hydrophilic and non-toxic.
 4. The method of claim 1, wherein the microspheres comprise at least one of N-tris-hydroxymethyl methylacrylamide, diethylaminoethylacrylamide, or N,N-methylene-bis-acrylamide.
 5. The method of claim 1, wherein the microspheres further comprise gelatin.
 6. The method of claim 1, wherein injecting a composition comprises injecting the composition through a needle of about 18 to about 26 gauge.
 7. The method of claim 1, wherein the acrylamide polymer or copolymer comprises from about 0.5% to about 20%, by molecular weight, of crosslinkers.
 8. The method of claim 1, wherein the average diameter of the microspheres after injection are about 1 to about 4 times the average diameter of the microspheres immediately prior to injection.
 9. The method of claim 1, wherein the composition comprises the microspheres in an amount from about 10% to about 90% by weight, and the biocompatible carrier in an amount from about 90% to about 10% by weight.
 10. The method of claim 1, wherein the composition comprises the microspheres in an amount from about 10% to about 50% by weight, and the biocompatible carrier in an amount from about 50% to about 90% by weight.
 11. The method of claim 1, wherein the composition is a suspension of the microspheres in the biocompatible carrier.
 12. The method of claim 1, wherein the biocompatible carrier comprises salts which include cations selected from at least one of the following: sodium, potassium, calcium, magnesium, iron, zinc, and ammonium in an amount of from about 0.01 M to about 5 M.
 13. The method of claim 1, wherein the composition further comprises at least one of: a therapeutic agent, a radiopacifying agent, a contrast medium, or mixtures thereof.
 14. The method of claim 13, wherein the agent or medium is bound to the microspheres.
 15. A kit for performing tissue bulking for the treatment of urinary incontinence or urinary reflux disease, comprising: a) a needle for injecting a liquid based composition and configured for insertion into a bladder sphincter or urethra, b) substantially spherical microspheres comprising at least one of an acrylamide polymer, an acrylamide derivative polymer, an acrylamide derivative copolymer, or mixtures thereof, and c) a biocompatible carrier.
 16. The kit of claim 15, wherein kit is configured for treatment of at least one of: bladder-neck hypermobility, urethra hypermobility, intrinsic sphincter deficiency, or vesicoureteral reflux. 17: The kit of claim 15, wherein the microspheres are biocompatible, swellable, hydrophilic and non-toxic. 18: The kit of claim 15, wherein the microspheres comprise at least one of N-tris-hydroxymethyl methylacrylamide, diethylaminoethylacrylamide, or N,N-methylene-bis-acrylamide. 19: The kit of claim 15, wherein the microspheres further comprise gelatin. 20: The kit of claim 15, wherein the needle is between about 18 to about 26 gauge. 